JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A REVIEW OF DRUG-RECEPTOR INTERACTIONS IN BIOLOGICAL SYSTEMS

[1]Ms. Garima Sharma, [2]Dr. Priya Bajaj, [3]Dr. Anjani Rani

[1]Department of Chemistry, Delhi, India;

[2]Assistant Professor, Department of Zoology, Govt. P G. College, Noida (UP);

[3]Head, Department of Zoology, Govt. P G. College, Noida (UP);

Corresponding Author-
Dr. Priya Bajaj
Department of Zoology
Govt. PG College, Noida

Abstract
Understanding the interactions between organic compounds and biological systems, particularly drug-receptor interactions, is a pivotal aspect of pharmacology, drug development and therapeutic applications. This review consolidates key insights the biological system to provide a comprehensive overview of drug-receptor interactions. The focus of this review paper spans from historical perspectives to cutting-edge computational and structural methodologies, emphasizing G protein-coupled receptors (GPCRs), allosteric modulation, and advanced drug discovery techniques.
This review aims to elucidate the complex interplay between drugs and receptors, drawing on a wealth of research to highlight the latest advancements and methodologies in this field. Receptors are macromolecules involved in chemical signalling between and within cells; they may be located on the cell surface membrane or within the cytoplasm. This paper discusses the principles of drug-receptor interactions, methodologies used to study these interactions, and recent advancements in this field. Receptor types, binding affinity and specificity, computational and experimental techniques, and case studies illustrating practical applications and challenges in drug-receptor research are the vital of drug receptor interface. This study is devoted to the assessment of scale-up issues and the increase in the technology readiness level of interactions between organic compounds and biological systems. An in-depth analysis of the mechanisms underlying these interactions, the methods used to study them might be useful in implicating them for drug design and development.

Key Words-: Drugs, Receptors, Drug-receptor interactions.

Introduction

Early pharmacological studies focused on empirical observations of drug effects without a clear understanding of the underlying mechanisms. The receptor theory proposed in the early 20th century, revolutionized pharmacology by suggesting that drugs bind to specific receptors to elicit responses. This conceptual shift laid the groundwork for modern drug design strategies. The discovery of specific receptor types, such as adrenergic and cholinergic receptors, provided tangible targets for drug action. Subsequent developments in receptor binding assays and molecular pharmacology have refined our understanding of drug-receptor interactions, enabling the design of more specific and effective drugs (Colquhoun et al.2006).
Drug-receptor interactions are the cornerstone of pharmacodynamics, determining the efficacy, specificity, and safety of therapeutic agents. Further, drug-receptor interactions are fundamental to understanding the mechanisms of drug action and the development of therapeutic agents. Receptors, primarily proteins, are the

target sites where drugs exert their effects (Kobilka et al.2007). The simplest concept is the analogy of a lock and key (receptor and drug), although receptor and drug structure are not necessarily rigid and may be relatively plastic. The most potent drug at a receptor will 'fit perfectly' and other drugs with similar but nonidentical structure may fit less effectively and therefore be less potent and have no effect, a partial effect or indeed inhibit (antagonize) the interaction of the reference drug (Page & Maddison, 2008).

At its core, drug-receptor interaction involves the specific recognition and binding of a drug molecule (ligand) to its target receptor. Receptors are typically proteins or protein complexes that are embedded in cell membranes or located intracellularly (Lefkowitz et al.2007). Ligand binding induces a conformational change in the receptor, triggering downstream signalling cascades or enzymatic activities that mediate physiological responses. Key principles governing drug-receptor interactions includes- Specificity, Affinity, and Efficacy. Drugs exhibit specificity for particular receptors based on complementary structural and chemical properties. This selectivity underpins the therapeutic efficacy and side-effect profiles of drugs. Whereas, affinity denotes the strength of binding between a drug and its receptor. Quantitatively, it is characterized by the dissociation constant (Kd), which reflects the concentration of drug required to occupy 50% of available receptors. Efficacy of a drug describes the ability of a drug-receptor complex to elicit a biological response. It can range from full agonism (maximal response) to partial agonism or antagonism (inhibition of response). (Gies and Landry, 2003)

Receptors

In the early 20th century, the concept of receptors was first proposed by Paul Ehrlich and John Langley, further, the concept of a "magic bullet" envisioned selective drug targeting based on receptor interactions. Work on the "receptive substance" conceptually introduced the idea of receptors as specific binding sites for drugs which laid the groundwork for the receptor theory. Receptors are specialized protein molecules embedded in the cell membrane or located intracellularly in cytoplasm. They bind to specific ligands, triggering a cascade of cellular responses. Cell surface receptors include G-protein-coupled receptors (GPCRs), ion channels, and receptor tyrosine kinases. Whereas, intracellular receptors include nuclear receptors and cytoplasmic receptors. The study of some common receptor might be supportive for elucidating the mechanisms of signal transduction and for the development of drugs that can modulate these processes (Miller and Lappin, 2022).

The most common G Protein-Coupled Receptors (GPCRs) represent one of the largest and most versatile families of receptors in the human body. They play a critical role in various physiological processes and are a major target for therapeutic drugs (Kobilka and Lefkowitz et al.2007). GPCRs share a common structural motif of seven transmembrane helices. They transduce extracellular signals through the activation of intracellular G proteins, which then initiate various signalling cascades. Advances in crystallography and cryo-electron microscopy have provided high-resolution structures of several GPCRs, revealing detailed insights into their activation mechanisms. Understanding GPCR structure-function relationships has been crucial in developing drugs for a range of conditions, from cardiovascular diseases to mental health disorders. Biophysical techniques like bioluminescence resonance energy transfer (BRET) aid in studying GPCR dynamics and ligand-induced conformational changes. Drug development targeting GPCRs includes β-blockers for cardiovascular diseases and antipsychotics acting on dopamine receptors. GPCRs regulate processes ranging from neurotransmission to immune response modulation, underscoring their therapeutic relevance. Structural elucidation of β2-adrenergic receptor bound to ligands revealed conformational changes upon activation (Wong etal., 2023).

Role of Protein-Ligand Interactions in Drug Design

The interaction between proteins and ligands is fundamental to drug action, thus important for successful drug design. Molecular recognition between proteins and ligands governed by non-covalent interactions like hydrogen bonds, van der Waals forces, and hydrophobic interactions that dictate binding specificity and affinity that are critical for effective drug action. Structural techniques such as X-ray crystallography and NMR spectroscopy provide insights into these interactions, guiding the optimization of drug candidates for enhanced therapeutic efficacy (Kubinyi et al.2004).

Rational drug design involves optimizing these interactions to enhance binding affinity and selectivity, thereby improving therapeutic efficacy, and reducing side effects. Fragment-based drug design identifies initial low-affinity fragments that are expanded and linked to enhance binding affinity and selectivity. Computational methods like molecular docking and QSAR models predict and optimize ligand-protein interactions, accelerating drug discovery pipelines. For example- HIV protease inhibitors illustrate structure-based optimization leading to potent antiviral drugs. Further, fragment-based approaches utilize docking to identify fragments binding to allosteric sites for drug development (Huggins etal., 2012).

Computational Approaches to Drug-Receptor Interactions

Computational methodologies revolutionizing drug discovery by predicting and analysing drug-receptor interactions. Molecular docking simulations predict ligand binding modes (how small molecules such as drugs bind to a receptor) thereby, facilitating virtual screening of large compound libraries. Molecular dynamics simulations elucidate dynamic interactions between drugs and receptors over time, offering insights into binding stability and conformational changes. Combining computational approaches with experimental data enhances the accuracy and efficiency of drug discovery processes. Integration of docking and MD simulations refines drug designs by considering receptor flexibility and solvent effects. Quantum mechanics or molecular mechanics (QM/MM) simulations explore enzymatic reactions, guiding structure-based drug design strategies and Machine learning algorithms enhance predictive models for pharmacokinetics and toxicity, complementing experimental studies in drug development (Sanner and Olson et al.2009). For example, insights into Ligand-Receptor Interactions via Molecular Docking Simulations includes molecular docking's application in elucidating ligand-receptor interactions, and it is crucial for structure-based drug design. Docking algorithms predict the preferred orientation of a ligand when it binds to a receptor, assessing binding affinity and stability. Case studies illustrate how docking simulations have been used to discover new inhibitors for enzymes like HIV protease and kinases. Docking results are often validated with experimental binding assays to ensure accuracy. Advances in docking algorithms have improved their ability to handle receptor flexibility and solvent effects, making them more reliable. Hybrid docking approaches integrate experimental data and computational simulations, validating predicted binding modes (Fu et al.2018).

Allosteric Modulation of Receptors: From Molecular Insights to Therapeutic Perspectives

Allosteric modulation involves the regulation of receptor activity by binding at sites other than the active site. The potential of allosteric modulators in drug development was explored with highlighting its advantages over ortho-steric targeting for receptor regulation (Pin et al.2009). Allosteric sites modulate receptor activity without directly competing with ortho-steric ligands, offering specificity and reduced side effects. Structural studies identify allosteric sites and inform rational drug design strategies targeting diverse receptor families. Allosteric drugs can fine-tune receptor responses, leading to more nuanced therapeutic effects. Functionally these therapeutic applications might be- **Positive allosteric modulators (PAMs)** enhance receptor responses, for example benzodiazepines potentiating GABAergic signalling in treating anxiety and **Negative allosteric modulators (NAMs)** attenuate receptor activity, such as mGluR5 antagonists for neurological disorders and in treating fragile X-syndrome. (Conn etal., 2009)

Innovative Approaches to Allosteric Modulation of GPCRs

The innovative strategies targeting GPCRs via allosteric modulation, expanding therapeutic possibilities primarily includes **biochemical approaches** identifying allosteric sites for receptor families like muscarinic acetylcholine receptors (mAChRs) and adenosine receptors. Recent advances have identified several GPCR allosteric modulators with therapeutic potential, such as modulators of the M1 muscarinic acetylcholine receptor for cognitive disorders. Pharmacological profiling assesses allosteric modulators' functional impact on receptor signalling cascades, guiding clinical development. Second approaches are **High-throughput screening and fragment-based approaches**, which identifies allosteric modulators with enhanced selectivity and potency, exemplifying drug discovery innovation (Conn and Lindsley et al.2009).

The use of biophysical methods, such as fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR), aids in characterizing allosteric binding sites and kinetics. The development of biased agonists, which selectively activate specific signalling pathways, represents a promising direction in allosteric modulation. (Brecht et al.2004)

Structure-Based Drug Designing: Docking and Scoring

Structure-based drug design (SBDD) leverages the three-dimensional structures of target proteins to design effective drugs. Molecular docking predicts ligand binding modes, guiding lead optimization through structure-activity relationships (SAR). Scoring functions evaluate docking poses based on binding affinities and drug-like properties, prioritizing promising drugs. Success stories include the design of HIV protease inhibitors and kinase inhibitors based on the structural information of their targets for example kinase inhibitors showcase SBDD's success in targeting oncogenic pathways for cancer therapy. Still the way of SBDD is challenging, which include accurately predicting receptor flexibility and dealing with the inherent limitations of scoring functions. Integrating SBDD with medicinal chemistry and pharmacokinetics/pharmacodynamics (PK/PD) studies enhances the drug development process. (Volkamer and Jacoby et al.2012)

The structure-based strategies in GPCR drug discovery, emphasizing receptor structure elucidation and ligand optimization. Several experimental techniques are employed to study drug-receptor interactions like- **X-ray Crystallography** provides high-resolution structures of drug-receptor complexes, revealing atomic details of the interaction, **Nuclear Magnetic Resonance (NMR) Spectroscopy** that Offers insights into the conformational changes and dynamics of receptors upon drug binding and **Cryo-Electron Microscopy,** which has revolutionized structural biology by enabling the visualization of drug-receptor complexes at near-atomic resolution in their native states (Wong et al.2021). These techniques have provided high-resolution structures of several GPCR structures, guiding Structure-Based drug design (SBDD) for orthosteric and allosteric ligand design, therefore, facilitating rational drug design. Homology modelling predicts GPCR structures for which no experimental structures are available, facilitating virtual screening and hit identification in drug discovery campaigns. (Marshall and Bräuner-Osbornen et al.2012)

Fragment-Based Drug Design:

Fragment-based drug design (FBDD) involves the identification and screening of small chemical fragments that bind to different parts of a target proteins/receptor and optimizing them into high-affinity potent drug. FBDD allows the identification of novel binding sites and the design of drugs with high specificity and affinity. FBDD has been successfully applied in the development of several FDA-approved drugs. It is particularly useful for targeting challenging receptors with small or poorly defined binding sites, offering a complementary approach to traditional high-throughput screening (Kirsch etal., 2019; Osborne et al.2020).

FBDD has led to the discovery of several clinical drugs including Vemurafenib for melanoma and Venetoclax for chronic lymphocytic leukemia. Methods such as X-ray crystallography, NMR spectroscopy, and fragment-based screening are used to identify low-molecular-weight fragments binding to protein targets. The success of FBDD relies on the identification of fragments with favourable binding properties and the ability to optimize them for potency and selectivity. Case studies of kinase inhibitors showcase FBDD's impact on targeting oncogenic pathways with enhanced selectivity and potency. Integration of computational and experimental approaches accelerates FBDD by predicting fragment binding modes and optimizing drug-like properties (Jhoti and Abell et al.2013).

Quantitative Structure-Activity Relationship (QSAR) Modelling in Drug Design

Quantitative structure-activity relationships (QSAR) modelling is a computational technique used to predict the biological activity of compounds based on their chemical structure, guiding drug design and optimization. QSAR models correlate chemical structure descriptors with biological activity, enabling the prediction of structure-activity relationships for new compounds (Soares etal., 2022). Techniques such as 2D-QSAR and 3D-QSAR provide different levels of structural detail into ligand interactions with receptors, enhancing predictive accuracy. QSAR modelling has been used to design inhibitors for various targets, including enzymes, receptors, and ion channels. Case studies of enzyme inhibitors illustrate QSAR's impact on optimizing drug potency and selectivity across diverse target classes. But there are certain challenges that includes the need for high-quality data and the development of robust and predictive models, addressed by advanced computational algorithms and experimental validation that can generalize across diverse chemical spaces (Tropsha and Golbraikh et al.2007).

High-Throughput Screening for Drug-Receptor Interactions:

High-throughput screening (HTS) is a powerful technique, pivotal in identifying drug-receptor interactions from large compound libraries. HTS technologies include fluorescence-based assays, mass spectrometry, and cell-based assays. HTS has been instrumental in identifying lead compounds for various targets, including GPCRs, kinases, and proteases. Case studies of kinase inhibitors demonstrate HTS's impact on identifying lead compounds targeting cancer pathways with high potency. Miniaturization and automation enhance HTS throughput, accelerating hit identification and lead optimization in drug discovery campaigns. Integration of computational modelling and structural studies validates HTS hits, guiding medicinal chemistry efforts toward clinical development (Szymanski et al.2012).

Pharmacokinetics and Pharmacodynamics of Allosteric Modulators

Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of allosteric modulators is crucial for optimizing therapeutic efficacy and safety. Allosteric modulators exhibit distinct PK/PD profiles compared to orthosteric drugs, influencing absorption, distribution, metabolism, and excretion (ADME) properties. Properties of allosteric modulators for targets such as GPCRs and ion channels highlight dose-response relationships and therapeutic windows for clinical efficacy. Development of allosteric modulators requires careful consideration of their dose-response relationships and potential for drug-drug interactions. Understanding, the PK/PD profiles

of allosteric modulators can inform dosing strategies and optimize therapeutic outcomes. PK/PD modelling integrates experimental data with computational simulations, optimizing allosteric modulator dosing strategies for therapeutic outcomes (Lutjens et al.2013).

Challenges in studying of Drug-Receptor Interactions

Though Drug-receptor interactions are fundamental to the pharmacological effects of drugs. These interactions involve the binding of drug molecules to specific receptors, initiating a cascade of biological responses. Despite significant progress in understanding these interactions, several challenges as follows that hinder the efficient development of new therapeutics. Some of them are- **Target Identification and Validation,** which is a complex process that significantly impacts the success rate of drug discovery. There are approximately 600-1500 druggable targets in the human genome that shows the challenge in pinpointing which targets are viable for therapeutic intervention (Overington et al.2006). Virtual Screening and Predictive Modelling is another challenge, which is a powerful tool but has its own set of limitations. This includes the difficulty in accurately predicting how small organic molecules will interact with biological targets, what reliable molecular docking protocols should be developed that are essential for predicting drug-receptor interactions accurately (Huang et al.2006; Shoichet et al.2004).

Understanding the kinetics and dynamics of drug-receptor interactions is crucial for drug efficacy and safety, for example complexities in studying the binding kinetics of dopamine D2 receptor antagonists are critical for the therapeutic effects of antipsychotics (Kapur and Seeman et al. 2001). Structural biology and receptor conformations has provided invaluable insights into drug-receptor interactions, yet obtaining high-resolution receptor structures remains challenging. There are difficulties in crystallizing membrane proteins, such as GPCRs, which are common drug targets. Also, it may encounter multiple receptor conformations during drug design, as receptors often exist in dynamic equilibrium between different states (Liu and Wang et al. 2015; Congreve et al. 2005).

Computational modelling and simulations have become an indispensable tool in studying drug-receptor interactions, but it has certain limitations. Confronts in using NMR spectroscopy to complement computational studies highlight the difficulties in interpreting complex spectra. The high attrition rates in drug development are a significant challenge, often resulting from the failure to translate preclinical findings to clinical success. The multifactorial reasons behind high attrition rates, including the complexity of drug-receptor interactions and unforeseen toxicities (Miller and Mayo et al. 2017; Kola and Landis et al. 2004).

Future Directions and Emerging Technologies:

Despite these challenges, ongoing advancements in technology and methodologies offer hope for overcoming these hurdles. By leveraging advancements in cryo-electron microscopy (cryo-EM), machine learning (ML) and artificial intelligence (AI), molecular dynamics (MD) simulations, quantum computing, multi-omics data integration, fragment-based drug design (FBDD), and single-cell technologies, researchers can address existing challenges and enhance the precision and efficiency of drug development.

Cryo-EM has emerged as a powerful tool for elucidating the structures of complex biological macromolecules at near-atomic resolution. The application of cryo-EM in drug discovery has significantly advanced our understanding of drug-receptor interactions and its utility showcased the detailed structures of receptors, which are critical for rational drug design. Cryo-EM allows researchers to visualize conformational changes in receptors upon ligand binding, aiding in the design of drugs that can precisely target these changes. This technology has been instrumental in the development of novel therapeutics for diseases such as cancer and neurological disorders, where precise receptor targeting is crucial. For example, high-resolution cryo-EM structures of the human GABA B receptor has offered insights into its activation mechanism and interaction with potential therapeutic compounds (Shihua He et al. 2021).

Machine learning (ML) and artificial intelligence (AI) are transforming drug discovery by enabling the analysis of vast datasets and the prediction of drug-receptor interactions with high accuracy. These technologies can analyse complex biological data, identify patterns, and generate predictive models that guide drug development. AI-driven drug discovery platforms can screen millions of compounds rapidly, identifying those with the highest likelihood of effective receptor binding. These tools are particularly valuable in early-stage drug discovery, where they can significantly reduce the time and cost associated with traditional experimental methods (Heather J. Kulik et al.2020).

Advances in molecular dynamics (MD) simulations provide detailed insights into the dynamic behaviour of drug-receptor interactions at the atomic level. These simulations can model the entire binding process, revealing transient states and intermediate conformations that are often inaccessible through experimental techniques. MD simulations help in optimizing drug candidates by predicting their binding affinity and stability. They are used

to explore the effects of mutations on receptor function and drug efficacy, aiding in the design of more potent and selective drugs (McCommon et al. 1977).
Quantum computing holds the potential to revolutionize drug discovery by enhancing the accuracy and efficiency of predicting drug-receptor interactions. The current status and future prospects of quantum computing in drug discovery been explored, highlighting its ability to solve complex problems that are intractable for classical computers. Quantum algorithms can simulate molecular interactions with unprecedented precision, providing insights into the fundamental mechanisms of drug action. Quantum computing can accelerate the discovery of new drugs by accurately modelling the electronic structures of molecules and their interactions with receptors. This technology is expected to play a crucial role in personalized medicine, where tailored therapies require precise understanding of individual molecular interactions (Tahir et al.2021).
The integration of multi-omics data (genomics, proteomics, metabolomics, etc.) with AI can enhance our understanding of drug-receptor interactions and facilitate personalized medicine. Multi-omics data integration can reveal comprehensive biological insights, enabling the identification of novel drug targets and biomarkers. By combining different layers of biological information, researchers can gain a holistic view of the molecular mechanisms underlying drug action. Multi-omics approaches can identify patient-specific factors that influence drug efficacy and toxicity, leading to more personalized and effective treatments. These methods are particularly valuable in complex diseases like cancer, where multiple molecular pathways are involved (Zhang et al.2019).
Single-cell technologies enable the analysis of drug-receptor interactions at the single-cell level, revealing heterogeneity in cellular responses to drugs. The application of single-cell technologies in drug discovery prominence their role in identifying cellular subpopulations and understanding differential drug responses. These technologies can provide detailed information on the variability of receptor expression and function across different cell types. Single-cell analysis is crucial for developing targeted therapies that account for cellular heterogeneity. It allows for the identification of resistant cell populations and the optimization of drug combinations to overcome resistance (He et al.2021).

Conclusion

The study of drug-receptor interactions is a multifaceted field that integrates structural biology, computational modelling, and pharmacological principles. Advances in these areas have significantly enhanced our understanding of how drugs interact with their targets, paving the way for the development of more effective and selective therapeutic agents. An insight from historical perspectives to modern computational and structural methodologies, this review highlights the current state of knowledge and identifies future directions for research in drug-receptor interactions. The study of drug-receptor interactions is fraught with challenges, from target identification and validation to the complexities of binding kinetics and structural biology. By addressing these challenges through technological advancements and innovative methodologies, we can improve our understanding of these critical interactions, ultimately leading to the development of more effective and safer therapeutics.
The future of drug discovery lies in the integration of advanced technologies such as cryo-EM, AI, MD simulations, quantum computing, multi-omics data integration, FBDD, and single-cell technologies. These innovations promise to address the current challenges in studying drug-receptor interactions, enhancing our knowledge, and enabling the development of more effective and personalized therapies. These emerging technologies can accelerate the drug discovery process and improve clinical outcomes. Advancements in the study of drug-receptor interactions have paved the way for the development of targeted therapies with improved efficacy and safety profiles. Ongoing research and the integration of computational and experimental approaches will continue to drive progress in this field, ultimately benefiting humankind.

References

1. Brecht M, Sewald K, Schiene K, Keen G, Fricke M, Sauer M, Niehaus K. The use of surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET) to monitor the interaction of the plant G-proteins Ms-Rac1 and Ms-Rac4 with GTP. J Biotechnol. 2004 Aug 26;112(1-2):151-64. doi: 10.1016/j.jbiotec.2004.04.030. PMID: 15288950.
2. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci. 2006 Mar;27(3):149-57. doi: 10.1016/j.tips.2006.01.008. Epub 2006 Feb 17. PMID: 16483674.
3. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009 Jan;8(1):41-54. doi: 10.1038/nrd2760. PMID: 19116626; PMCID: PMC2907734.

4. Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci. 2001 Oct;22(10):532-7. doi: 10.1016/s0165-6147(00)01799-5. PMID: 11583811.
5. Fu Y, Zhao J, Chen Z. Insights into the Molecular Mechanisms of Protein-Ligand Interactions by Molecular Docking and Molecular Dynamics Simulation: A Case of Oligopeptide Binding Protein. Comput Math Methods Med. 2018 Dec 4;2018:3502514. doi: 10.1155/2018/3502514. PMID: 30627209; PMCID: PMC6305025.
6. Gies J.P., Landry, Y. (2003) Drug Target: Molecular mechanism of drug action. In: The Practice of Medicinal Chemistry (Second Edition). Pages, 51-65. https://doi.org/10.1016/B978-012744481-9/50008-8
7. Gilson, M. K., & Honig, B. et al. 2002. Mechanisms of Drug-Receptor Interactions: From Binding to Function. Current Opinion in Structural Biology, 12(2), 204-213. https://doi.org/10.1016/S0959-440X(02)00355-4
8. Harren Jhoti, et al. 2020. Fragment-based drug discovery: success stories and future challenges. Nature Reviews Drug Discovery. DOI: 10.1038/s41573-020-00092-6
9. Heather J. Kulik, et al. 2020. Machine learning for molecular and materials science. Nature Reviews Chemistry. DOI: 10.1038/s41570-020-00215-8
10. Hebert, T., & Bouvier, M. et al. 2007. Allosteric Modulators of GPCRs: Drug Design and Therapeutic Potential. Nature Reviews Drug Discovery, 6(9), 733-749. https://doi.org/10.1038/nrd2269
11. Hillisch, A., & Hilgenfeld, R. et al. 2004. Molecular Mechanisms of Drug Action: Insights from Structure-Activity Relationships. Nature Reviews Drug Discovery, 3(11), 973-983. https://doi.org/10.1038/nrd1348
12. Huggins D.J., Sherman W., Tidor B. (2012) Rational Approaches to Improving Selectivity in Drug Design. J Med Chem., 55(4): 1424-1444.
13. Jeffrey Conn, P., Christopoulos, A. & Lindsley, C. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat Rev Drug Discov* **8**, 41–54 (2009). https://doi.org/10.1038/nrd2760
14. Jhoti, H., Abell, C., et al. 2013. Advances in Fragment-Based Drug Design: Methods, Validation, and Applications. Nature Reviews Drug Discovery, 12(8), 644-660. https://doi.org/10.1038/nrd3480
15. Kirsch P, Hartman AM, Hirsch AKH, Empting M. Concepts and Core Principles of Fragment-Based Drug Design. Molecules. 2019 Nov 26;24(23):4309. doi: 10.3390/molecules24234309. PMID: 31779114; PMCID: PMC6930586.
16. Kobilka, B. K., & Lefkowitz, R. et al.2007. G Protein-Coupled Receptors: Structure and Function. Annual Review of Pharmacology and Toxicology, 47, 263-299. https://doi.org/10.1146/annurev.pharmtox.47.120505.105225
17. Kollman, R. W. K., Shaw, D. E., et al. 2013. Computational Modeling of GPCRs: Advances and Challenges. Trends in Pharmacological Sciences, 34(7), 385-392. https://doi.org/10.1016/j.tips.2013.08.004
18. Kubinyi, H. et al.2004. The Role of Protein-Ligand Interactions in Drug Design. Nature Reviews Drug Discovery, 3(9), 711-715. https://doi.org/10.1038/nrd1344
19. Langer, T., & Süssmuth, R. D. et al.2005. Understanding Drug-Receptor Interactions with Pharmacophore Modeling. Drug Discovery Today, 10(23-24), 1555-1565. https://doi.org/10.1016/j.drudis.2005.10.005
20. Lefkowitz, R. J., Lefkowitz, R. J., et al. 2012. Biased Agonism in Drug Discovery: Mechanisms and Therapeutic Potential. Nature Reviews Drug Discovery, 11(5), 354-366. https://doi.org/10.1038/nrd3657
21. Lewis, R. J., & Vetter, I. N. et al. 2012. Structure-Function Relationship of Ion Channels and Receptors in Drug Design. Journal of Medicinal Chemistry, 55(8), 3758-3770. https://doi.org/10.1021/jm200641d
22. Lütjens, R., Perry, B., Schelshorn, D., Rocher, J. P. (2013) New technologies enabling the industrialization of allosteric modulator discovery. Drug Discovery Today: Technologies, 10(2): 253-260.
23. Marshall, F. H., Andrews, F. J., et al. 2013. The Evolution of GPCR Drug Discovery: From High-Throughput Screening to Structure-Based Design. Trends in Pharmacological Sciences, 34(3), 145-153. https://doi.org/10.1016/j.tips.2012.11.003
24. Marshall, F. H., Bräuner-Osborne, A. M., et al. 2012. Structure-Based Approaches to GPCR Drug Discovery. Methods, 55(4), 293-299. https://doi.org/10.1016/j.ymeth.2011.12.002
25. McCammon JA, Gelin BR, Karplus M. Dynamics of folded proteins. *Nature.* 1977;**267**(5612):585–590.
26. McCammon, J. A. et al. 2011. Ligand Binding and Molecular Dynamics Simulations in Drug Discovery. Current Opinion in Structural Biology, 21(2), 199-207. https://doi.org/10.1016/j.sbi.2011.01.007

27. Miller EJ, Lappin SL. (2022) Physiology, Cellular Receptor. In: Stat Pearls. https://www.ncbi.nlm.nih.gov/books/NBK554403/
28. Muhammad Tahir, et al. 2021. Applications of quantum computing in drug discovery: Current status and future prospects. Journal of Chemical Information and Modelling. DOI: 10.1021/acs.jcim.0c01402
29. Neubig, R., Jacobson, K. A., et al. 2013. Emerging Concepts in Allosteric Modulation of GPCRs. Nature Chemical Biology, 9(7), 459-464. https://doi.org/10.1038/nchembio.1232
30. Osborne J, Panova S, Rapti M, Urushima T, Jhoti H. Fragments: where are we now? Biochem Soc Trans. 2020 Feb 28;48(1):271-280. doi: 10.1042/BST20190694. PMID: 31985743.
31. Page S.W. Maddison J.E. (2008) Principles of clinical pharmacology, In: Small Animal Clinical Pharmacology (Second Edition)
32. Pin, J. P., & Binet, J. L. et al. 2009. Allosteric Modulation of Receptors: From Molecular Insights to Therapeutic Perspectives. Nature Reviews Drug Discovery, 8(8), 689-703. https://doi.org/10.1038/nrd2876
33. Ping Zhang, et al. 2019. Integrating multi-omics and artificial intelligence for next-generation molecular medicine. Nature Communications. DOI: 10.1038/s41467-019-10542-4
34. Shihua He, et al. 2021. Cryo-EM structures of human GABA B receptor. Nature. DOI: 10.1038/s41586-021-03425-5
35. Shoichet, B. K., & Walters, W. P. et al.2011. Allosteric Regulation of Receptors: Structural Insights and Drug Discovery. Nature Reviews Drug Discovery, 10(8), 543-550. https://doi.org/10.1038/nrd3448
36. Soares T.A., Alvis, A.N., Mazzolari A., Ruggui F., Wei G.W., Merz K. (2022) The (Re)-Evolution of Quantitative Structure–Activity Relationship (QSAR) Studies Propelled by the Surge of Machine Learning Methods. J. Chem. Inf. Model., 62, 22, 5317–5320
37. Stevens, R. C., & Chang, G. et al.2009. Insights into GPCR-Ligand Binding from High-Resolution Structures. Nature Reviews Molecular Cell Biology, 10(9), 637-650. https://doi.org/10.1038/nrm2842
38. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci. 2012;13(1):427-52. doi: 10.3390/ijms13010427. Epub 2011 Dec 29. PMID: 22312262; PMCID: PMC3269696.
39. Tropsha, A., & Golbraikh, O. A. et al.2007. Quantitative Structure-Activity Relationship (QSAR) Modeling in Drug Design. Current Topics in Medicinal Chemistry, 7(5), 441-458. https://doi.org/10.2174/156802607780619962
40. Volkamer, A., Jacoby, E., et al. 2012. Structure-Based Drug Design: Docking and Scoring. Drug Discovery Today, 17(21-22), 1037-1047. https://doi.org/10.1016/j.drudis.2012.01.017
41. Wong TS, Li G, Li S, Gao W, Chen G, Gan S, Zhang M, Li H, Wu S, Du Y. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct Target Ther. 2023 May 3;8(1):177. doi: 10.1038/s41392-023-01427-2. PMID: 37137892; PMCID: PMC10154768.
42. Xiaoxiao He, et al. 2021. Single-cell technologies in drug discovery: From target identification to clinical trials. Trends in Pharmacological Sciences. DOI: 10.1016/j.tips.2020.12.007